Search results for "slas europe 2018"

In this guest editorial, Dr. Ed Connor discusses the options available to GC labs looking to end or reduce helium consumption

Vireo™ promises to enable high-speed, AI-driven live-cell imaging for drug discovery

Provides helper phage function in packaging a common phage display phagemid. Infection of bacteria via pIII.

Explore the products you’ve told us are advancing science and research in Life Sciences

Elevate your 3D research with Gri3D ® , the ready-to-use microwell plate designed for highthroughput, reproducible organoid culture. Based on a standard 96-microtiter plate, each well contains an ultra-dense U-bottom microwell array patterned in a cell-repellent hydrogel. Organoids are robustly generated in microwells, where they grow in suspension-like conditions and are located in the same imaging plane. A pipetting port on…

Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan

Data shows that iota-carrageenan might be an effective virus blocker irrespective of present and possible future SARS-CoV-2 mutations

Dr. Stanley F. Lo, DABCC, FADLM, has been elected to serve on the ADLM board of directors as president-elect starting in August 2025

Starlab is organising a series of international events to promote sustainability in laboratories

The Mag-Bind cfDNA LSP Kit was showcased at SLAS2025 International Conference & Exhibition in San Diego, California

Droplet Digital PCR System, includes droplet generator, droplet reader, laptop computer, software, associated component consumables, for EvaGreen or probe-based digital PCR applications

Revvity is set to unveil its new Phenologic.AI software at SLAS2025 International Conference & Exhibition in San Diego, California

Allows improved identification of partial RhD types, including DOL, DCS, DMH, DHK/DAU-4, weak D types 1 and 2 as well as DMHi.

Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC

Partnership will center on Prescient Medicine's novel genetic testing technology designed to objectively assess an individual's risk of opioid addiction